Storia in 7 fonti

Pfizer raises sales guidance on high demand for older drugs

Drugmaker plans for another $2.5bn in cost savings as it looks to move beyond post-Covid sales slump

Raccontata da

economictimes.indiatimes.com

benzinga.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

irishtimes.comStai leggendo17 h fa

Pfizer raises sales guidance on high demand for older drugs

Drugmaker plans for another $2.5bn in cost savings as it looks to move beyond post-Covid sales slump

originale

Timeline cronologica

swissinfo.ch

19 h fa

Pfizer Raises Sales Guidance on High Demand for Older Drugs

(Bloomberg) -- Pfizer Inc. raised the midpoint of its 2026 sales forecast after reporting strong second-quarter demand for older medicines.

Leggi questa versione → originale

arabnews.com17 h fa

Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

GENEVA: Pfizer on Tuesday reported better-than-expected second-quarter results, boosted by strong demand for blood thinner Eliquis, and unveiled plans for an additional $2.5 billion in savings through its ongoing…

Leggi questa versione → originale

cnbc.com18 h fa

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Pfizer said it cut its full-year revenue expectation for its Covid products to $4 billion, down from around $5 billion previously.

Leggi questa versione → originale

economictimes.indiatimes.com14 h fa

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer beat Q2 earnings on strong Eliquis sales, announcing $2.5B in additional cost cuts and focusing on new obesity/cancer drugs for post-2028 growth. Metsera acquisition signals Big Pharma's shift to AI-driven precision medicine, targeting the $150B+ obesity market and reshaping biopharma R&D.

Leggi questa versione → originale

benzinga.com13 h fa

What's Going on With Pfizer Stock Tuesday? - Pfizer (NYSE:PFE)

Pfizer beat Q2 (EPS 77¢ vs 69¢) and raised FY2026 guidance to $60.5–62.5B. Strategic acquisitions in oncology/obesity signal post-COVID shift; Metsera approval target 2028 exemplifies pivot toward specialty therapeutics and emerging clinical markets.

Leggi questa versione → originale

martedì 4 agosto 2026·

arabnews.com

Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

GENEVA: Pfizer on Tuesday reported better-than-expected second-quarter results, boosted by strong demand for blood thinner Eliquis, and unveiled plans for an additional $2.5…

martedì 4 agosto 2026·

irishtimes.com

Pfizer raises sales guidance on high demand for older drugs

Drugmaker plans for another $2.5bn in cost savings as it looks to move beyond post-Covid sales slump

martedì 4 agosto 2026·

fiercepharma.com

Pfizer unveils additional $2.5B in planned cost savings through 2029

Pfizer will reduce its costs by $2.5 billion in another round of cutbacks which will kick in next year and run through 2029. | Pfizer will reduce its costs by $2.5 billion in…

martedì 4 agosto 2026·

economictimes.indiatimes.com

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in…

martedì 4 agosto 2026·

benzinga.com

What's Going on With Pfizer Stock Tuesday? - Pfizer (NYSE:PFE)

Pfizer stock rises after beating Q2 estimates and raising its 2026 revenue guidance to up to $62.5B. Get the key earnings takeaways.